Redpoint Investment Management’s NovoCure NVCR Stock Holding History

Redpoint Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$222K	Buy	+2,927	New	+$228K	0.03%	541
2021 Q4	–	Sell	-2,127	Closed	-$247K	–	651
2021 Q3	$247K	Hold	2,127	–	–	0.02%	601
2021 Q2	$472K	Buy	2,127 +527	+33%	+$103K	0.04%	472
2021 Q1	$211K	Hold	1,600	–	–	0.02%	637
2020 Q4	$277K	Buy	+1,600	New	+$219K	0.03%	494

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Redpoint Investment Management's NVCR Position: Q3 2022 in Review

Redpoint Investment Management opened a new position in NovoCure (NVCR) in Q3 2022: 2,927 shares worth $222K. The stake represents 0.03% of the portfolio and ranks #541 among its holdings. This is a return to the name: Redpoint Investment Management previously reported a position in NVCR as recently as Q3 2021.

Redpoint Investment Management first reported a position in NVCR in Q4 2020 and has held it in 5 quarters since. The position peaked at $472K in Q2 2021. 303 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

Redpoint Investment Management held 2,927 shares of NovoCure worth $222K as of Q3 2022.
NovoCure was a new Redpoint Investment Management position in Q3 2022.
NovoCure made up 0.03% of Redpoint Investment Management's portfolio in Q3 2022, its #541 holding.
Redpoint Investment Management first reported a position in NovoCure in Q4 2020 and has held it in 5 quarters since.
Redpoint Investment Management's NovoCure position peaked at $472K in Q2 2021.
303 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on Redpoint Investment Management's 13F filing for Q3 2022, filed 14 Oct 2022.